The androgen receptor (AR) antibody reacts with full length and the A-form of the receptor. It is known to be highly specific and does not cross-react with estrogen, progesterone or glucocorticoid receptors. It has been reported that well-differentiated tumors show high expression of Androgen Receptor and poorly differentiated tumors show low to no expression. In prostate cancer, androgen has been proposed as a marker of hormone-responsiveness, as high expression of Androgen Receptor in biopsies may help identify patients that would respond to androgen ablation therapy. Other applications for Androgen Receptor antibody include breast cancer, Paget’s disease and dermatopathology.
|Download IVD Data Sheet
|Download RUO Data Sheet for International
|Download SDS Sheet
Regulatory Notice: Biocare’s IVD-labeled products comply with US-FDA and European IVDD regulation. Other regions may have additional requirements for such labeling, please contact your local distributor.
1. Suwabe H, et al. Pathol Int. 1999 May; 49(5):391-402. 2. Cui D, et al. Pathol Int. 1998 May; 48(5):362-7. 3. Wagrowska-Danilewicz M, Danilewicz M. Acta Histochem. 1996 Jul; 98(3):301-8. 4. Linke RP, Gӓrtner HV, Michels H. J Histochem Cytochem. 1995 Sep; 43(9):863-9. 5. Ko LW, Sheu KF, Blass JP. Am J Pathol. 1991 Sep; 139(3):523-33. 6. Hind CR, et al. J Pathol. 1983 Feb; 139(2):159-66.